TGFβ Controls Ovarian Cancer Cell Proliferation.
OA: gold
CC-BY-4.0
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (49)
- Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. via crossref
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm via crossref
- Oocyte-somatic cell interactions in the human ovary-novel role of bone morphogenetic proteins and growth differentiation factors. via crossref
- Rethinking ovarian cancer: recommendations for improving outcomes. via crossref
- Telomere length in different histologic types of ovarian carcinoma with emphasis on clear cell carcinoma. via crossref
- The biology of ovarian cancer: new opportunities for translation. via crossref
- The cell of origin of ovarian epithelial tumours. via crossref
- doi:10.1002/path.2091 via crossref
- doi:10.1073/pnas.1017300108 via crossref
- doi:10.1158/2159-8290.cd-16-0607 via crossref
- doi:10.18632/genesandcancer.109 via crossref
- doi:10.1530/rep.1.01074 via crossref
- doi:10.1016/j.mce.2015.08.011 via crossref
- doi:10.1016/s0303-7207(01)00584-6 via crossref
- doi:10.1002/ijc.30233 via crossref
- doi:10.1128/mcb.00732-08 via crossref
- doi:10.1210/me.2015-1103 via crossref
- doi:10.1128/mcb.01404-07 via crossref
- doi:10.1016/j.cellsig.2010.10.015 via crossref
- doi:10.1016/j.biocel.2009.10.016 via crossref
- doi:10.1007/s00432-009-0703-4 via crossref
- doi:10.1200/jco.2003.11.524 via crossref
- doi:10.1038/ncomms3977 via crossref
- doi:10.1093/annonc/mdw007 via crossref
- doi:10.1158/2159-8290.cd-14-0275 via crossref
- doi:10.1158/1541-7786.mcr-07-0294 via crossref
- doi:10.1186/s12935-014-0072-1 via crossref
- doi:10.3892/or.2011.1151 via crossref
- doi:10.1002/(sici)1096-9896(200004)190:5<579::aid-path548>3.0.co;2-i via crossref
- doi:10.1002/ijc.2910520516 via crossref
- doi:10.1007/s00432-015-1998-y via crossref
- doi:10.1517/14728222.2013.749863 via crossref
- doi:10.1016/j.ccr.2006.11.023 via crossref
- doi:10.1038/sj.onc.1206617 via crossref
- doi:10.3892/or.2014.3580 via crossref
- doi:10.1038/nm.2619 via crossref
- doi:10.1098/rsob.120063 via crossref
- doi:10.1038/ncb2522 via crossref
- doi:10.1038/onc.2011.384 via crossref
- doi:10.1158/1078-0432.ccr-10-2429 via crossref
- doi:10.1016/j.pharmthera.2014.11.001 via crossref
- doi:10.1016/s1470-2045(07)70245-0 via crossref
- doi:10.1371/annotation/c943a596-3965-4a5b-a27c-55c16685ea32 via crossref
- doi:10.1016/j.ejca.2009.12.014 via crossref
- doi:10.3109/0284186x.2011.653437 via crossref
- doi:10.1007/s00428-012-1203-5 via crossref
- doi:10.1097/pas.0b013e3181cf3d79 via crossref
- doi:10.1038/nrc.2016.113 via crossref
- doi:10.1097/01.pas.0000180854.28831.77 via crossref
Source provenance
- crossref
- last seen: 2026-06-20T06:35:05.197968+00:00
- europepmc
- last seen: 2026-06-23T06:15:44.889181+00:00
- unpaywall
- last seen: 2026-05-21T02:00:01.467718+00:00
License: CC-BY-4.0